Research programme: protein-targeted antibody therapies - PolyTherics

Drug Profile

Research programme: protein-targeted antibody therapies - PolyTherics

Alternative Names: HiPEG™ IFN alpha-2a; Recombinant his-tagged IFN alpha-2a - PolyTherics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator PolyTherics
  • Class Antibodies; Biological proteins
  • Mechanism of Action Interferon alfa 2a stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • No development reported Hepatitis C; Unspecified

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in United Kingdom (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Undefined in United Kingdom (Parenteral)
  • 07 Sep 2010 HiPEG™ IFN alpha-2a is available for licensing for hepatitis C as of 07 Sep 2010. www.polytherics.co.uk
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top